LLY
$906.70-10.80 (-1.18%)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally.
Recent News
Is This Stock a Buy on the Dip?
This company has a habit of beating the market over long periods.
Eli Lilly Taps Fauna Bio AI To Expand Long Term Obesity Strategy
Fauna Bio and Eli Lilly (NYSE:LLY) identified a new obesity drug target using AI insights from hibernating mammals. The target designation advances their existing discovery partnership focused on metabolic disease. This development adds a non GLP 1 related angle to Eli Lilly's obesity research efforts. Eli Lilly, known for its diabetes and obesity treatments, is already a central player in the fast growing weight management drug space. The new AI derived target with Fauna Bio gives the...
Beijing courts Eli Lilly as weight-loss drug race drives $3bn China commitment
Investing.com -- Eli Lilly and Company (NYSE:LLY) is deepening its footprint in the world’s second-largest economy, with Chinese Commerce Minister Wang Wentao expressing hope that the pharmaceutical giant will "deepen its commitment" and pursue more aggressive growth targets.
Big drugmakers saved at least $5bn on US taxes shifting income overseas
Ten of the biggest US pharmaceutical and biotech companies cut at least $5bn from their federal tax bills last year by booking income in low...
Market Madness: Palantir, Walmart, & other hot stock picks
In the second installment of Yahoo Finance's "Market Madness" bracket tournament, Zack's Investment Management chief market strategist Brian Mulberry joins Yahoo Finance Head of News Myles Udland to make the case for this round of corporate match-ups, which includes Robinhood (HOOD) vs. UnitedHealth (UNH) Palantir (PLTR) vs. Procter & Gamble (PG), General Motors (GM) vs. Eli Lilly (LLY), Walmart (WMT) vs. Uber (UBER), and more.